| 000 | 01518 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517185042.0 | ||
| 264 | 0 | _c20181001 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1742-7843 | ||
| 024 | 7 |
_a10.1111/bcpt.12933 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMurray, Michael | |
| 245 | 0 | 0 |
_aVariation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. _h[electronic resource] |
| 260 |
_bBasic & clinical pharmacology & toxicology _cApr 2018 |
||
| 300 |
_a388-395 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xmetabolism |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aClozapine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP1A2 _xmetabolism |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP1A2 Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xmetabolism |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aFluvoxamine _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydroxylation |
| 650 | 0 | 4 |
_aKetoconazole _xpharmacology |
| 650 | 0 | 4 |
_aLiver _xcytology |
| 650 | 0 | 4 |
_aMicrosomes, Liver _xdrug effects |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 700 | 1 | _aZhang, Wei V | |
| 700 | 1 | _aEdwards, Robert J | |
| 773 | 0 |
_tBasic & clinical pharmacology & toxicology _gvol. 122 _gno. 4 _gp. 388-395 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bcpt.12933 _zAvailable from publisher's website |
| 999 |
_c27805552 _d27805552 |
||